Aliskiren and valsartan dose-escalation study in essential hypertension

Phase 3, randomised, double-blind trial of aliskiren and valsartan in essential hypertension (5 arms), sponsored by Novartis. Primary endpoints: Change from baseline to Week 8 endpoint in mean sitting diastolic blood pressure and Superior reduction in mean sitting diastolic blood pressure for aliskiren 300 mg + valsartan 320 mg versus both monotherapy components. Started Sep 2005; status: completed.